235 related articles for article (PubMed ID: 31881315)
1. Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review.
Kumari R; Sunil D; Ningthoujam RS
J Control Release; 2020 Mar; 319():135-156. PubMed ID: 31881315
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-responsive nanoparticles for tumor-targeted drug delivery.
Li Y; Jeon J; Park JH
Cancer Lett; 2020 Oct; 490():31-43. PubMed ID: 32585414
[TBL] [Abstract][Full Text] [Related]
3. Oxygenated theranostic nanoplatforms with intracellular agglomeration behavior for improving the treatment efficacy of hypoxic tumors.
Zhou J; Xue C; Hou Y; Li M; Hu Y; Chen Q; Li Y; Li K; Song G; Cai K; Luo Z
Biomaterials; 2019 Mar; 197():129-145. PubMed ID: 30641264
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-responsive nanocarriers for cancer imaging and therapy: recent approaches and future perspectives.
Thambi T; Park JH; Lee DS
Chem Commun (Camb); 2016 Jun; 52(55):8492-500. PubMed ID: 27225824
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-active nanoparticles used in tumor theranostic.
Wang Y; Shang W; Niu M; Tian J; Xu K
Int J Nanomedicine; 2019; 14():3705-3722. PubMed ID: 31190820
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-activated nanomedicines for effective cancer therapy.
Zhou M; Xie Y; Xu S; Xin J; Wang J; Han T; Ting R; Zhang J; An F
Eur J Med Chem; 2020 Jun; 195():112274. PubMed ID: 32259703
[TBL] [Abstract][Full Text] [Related]
7. Integration of cascade delivery and tumor hypoxia modulating capacities in core-releasable satellite nanovehicles to enhance tumor chemotherapy.
Wang J; Wang X; Lu SY; Hu J; Zhang W; Xu L; Gu D; Yang W; Tang W; Liu F; Cao Y; Liu H
Biomaterials; 2019 Dec; 223():119465. PubMed ID: 31518842
[TBL] [Abstract][Full Text] [Related]
8. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer.
Yasuda H
Nitric Oxide; 2008 Sep; 19(2):205-16. PubMed ID: 18503779
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor hypoxia with stimulus-responsive nanocarriers in overcoming drug resistance and monitoring anticancer efficacy.
Xie Z; Guo W; Guo N; Huangfu M; Liu H; Lin M; Xu W; Chen J; Wang T; Wei Q; Han M; Gao J
Acta Biomater; 2018 Apr; 71():351-362. PubMed ID: 29545193
[TBL] [Abstract][Full Text] [Related]
10. Designing Hypoxia-Responsive Nanotheranostic Agents for Tumor Imaging and Therapy.
Zhou H; Qin F; Chen C
Adv Healthc Mater; 2021 Mar; 10(5):e2001277. PubMed ID: 32985141
[TBL] [Abstract][Full Text] [Related]
11. Extremely Effective Chemoradiotherapy by Inducing Immunogenic Cell Death and Radio-Triggered Drug Release under Hypoxia Alleviation.
Zhu C; Guo X; Luo L; Wu Z; Luo Z; Jiang M; Zhang J; Qin B; Shi Y; Lou Y; Qiu Y; You J
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46536-46547. PubMed ID: 31751119
[TBL] [Abstract][Full Text] [Related]
12. Redox Potential and ROS-Mediated Nanomedicines for Improving Cancer Therapy.
Glass SB; Gonzalez-Fajardo L; Beringhs AO; Lu X
Antioxid Redox Signal; 2019 Feb; 30(5):747-761. PubMed ID: 28990403
[TBL] [Abstract][Full Text] [Related]
13. Modulating tumor hypoxia by nanomedicine for effective cancer therapy.
Jahanban-Esfahlan R; de la Guardia M; Ahmadi D; Yousefi B
J Cell Physiol; 2018 Mar; 233(3):2019-2031. PubMed ID: 28198007
[TBL] [Abstract][Full Text] [Related]
14. Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy.
Li Y; Ding J; Xu X; Shi R; Saw PE; Wang J; Chung S; Li W; Aljaeid BM; Lee RJ; Tao W; Teng L; Farokhzad OC; Shi J
Nano Lett; 2020 Jul; 20(7):4857-4863. PubMed ID: 32479088
[TBL] [Abstract][Full Text] [Related]
15. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
16. Mesoporous nanocarriers with a stimulus-responsive cyclodextrin gatekeeper for targeting tumor hypoxia.
Lee J; Oh ET; Yoon H; Kim CW; Han Y; Song J; Jang H; Park HJ; Kim C
Nanoscale; 2017 May; 9(20):6901-6909. PubMed ID: 28503686
[TBL] [Abstract][Full Text] [Related]
17. Oxygen-Self-Produced Nanoplatform for Relieving Hypoxia and Breaking Resistance to Sonodynamic Treatment of Pancreatic Cancer.
Chen J; Luo H; Liu Y; Zhang W; Li H; Luo T; Zhang K; Zhao Y; Liu J
ACS Nano; 2017 Dec; 11(12):12849-12862. PubMed ID: 29236476
[TBL] [Abstract][Full Text] [Related]
18. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle Delivery of MnO
Chang CC; Dinh TK; Lee YA; Wang FN; Sung YC; Yu PL; Chiu SC; Shih YC; Wu CY; Huang YD; Wang J; Lu TT; Wan D; Chen Y
ACS Appl Mater Interfaces; 2020 Oct; 12(40):44407-44419. PubMed ID: 32865389
[TBL] [Abstract][Full Text] [Related]
20. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance.
Yang J; Li W; Luo L; Jiang M; Zhu C; Qin B; Yin H; Yuan X; Yin X; Zhang J; Luo Z; Du Y; You J
Biomaterials; 2018 Nov; 182():145-156. PubMed ID: 30121013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
